Amy Becker, MD
Pediatric Nephrology · Corpus Christi, TXNPI 1124037643
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $50,311 of the $77,342 with a category attached, or 65.1%. Sanofi accounts for 98.7% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $29,125 and has fallen 55.6% since, to $12,937 in 2024. Among pediatric nephrology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 103 payments — averaging $750.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$76K
- AstraZeneca$457
- GSK$146
- Aurinia Pharma U.S., Inc.$119
- Ultragenyx Pharmaceutical Inc.$80
- Amicus Therapeutics, Inc.$69
- plus $154 from 7 others
Across 78 payments — averaging $528.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Travere Therapeutics, Inc.$41K
What the payments were for
- Consulting fees$14,40019%
- Speaking & faculty fees$50,31165%
- Travel & lodging$10,15913%
- Food & beverage$2,4123%
- Education$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 69 | $76,315 |
| AstraZeneca | 11 | $457 |
| GSK | 3 | $146 |
| Aurinia Pharma U.S., Inc. | 6 | $119 |
| Ultragenyx Pharmaceutical Inc. | 3 | $80 |
| Amicus Therapeutics, Inc. | 4 | $69 |
| Novo Nordisk | 1 | $36 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| Kyowa Kirin, Inc. | 1 | $26 |
| Spacelabs Healthcare Inc | 1 | $22 |
| Silvergate Pharmaceuticals, Inc. | 1 | $18 |
| Tolmar, Inc. | 1 | $13 |
| Azurity Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$77,342 in reported general payments places this provider in the 95th percentile of 61 pediatric nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Calcitriol | 11 | $1,897 |
| Methenamine Hippurate | 13 | $737 |
| Leflunomide | 12 | $442 |
| Enalapril Maleate | 12 | $239 |
| Ondansetron OdtOndansetron | 15 | $150 |
| Amoxicillin | 43 | $116 |
| Prednisone | 19 | $111 |
| Lisinopril | 11 | $32 |
| Clonidine Hcl | 12 | $21 |
| Amlodipine Besylate | 20 | $13 |
Paid to pharmacies, not to this prescriber.
Other pediatric nephrology in Corpus Christi
- Samhar Al AkashCorpus Christi$9K
- Franca Tilley-GyadoCorpus Christi$713
- Salam GharaybehCorpus Christi$609
- Fredrick McCurdyCorpus Christi$485
- Mini MichaelHouston$25K
- Rita SwinfordHouston$25K
- Ewa ElenbergHouston$16K
- Robert GillespieFort Worth$11K
- Melissa CadnapaphornchaiSan Antonio$10K
- Raymond QuigleyDallas$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.